Drug profile · INN
coronavirus (sars-cov-2) rna vaccine (active ingredient: ufrenmeran)
DAICHIRONA (MONOVALENT, ORIGINAL) INITIAL APPROVAL
coronavirus (sars-cov-2) rna vaccine (active ingredient: ufrenmeran) (DAICHIRONA (MONOVALENT, ORIGINAL) INITIAL APPROVAL) is an FDA-listed pharmaceutical active ingredient.
Drug details — coronavirus (sars-cov-2) rna vaccine (active ingredient: ufrenmeran)
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.78
Quick answer
coronavirus (sars-cov-2) rna vaccine (active ingredient: ufrenmeran) (DAICHIRONA (MONOVALENT, ORIGINAL) INITIAL APPROVAL) is an FDA-listed pharmaceutical active ingredient.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| PMDA | approved | — |
Pipeline programs
Frequently asked questions
What is coronavirus (sars-cov-2) rna vaccine (active ingredient: ufrenmeran)?
coronavirus (sars-cov-2) rna vaccine (active ingredient: ufrenmeran) (DAICHIRONA (MONOVALENT, ORIGINAL) INITIAL APPROVAL) is an FDA-listed pharmaceutical active ingredient.
What is the brand name for coronavirus (sars-cov-2) rna vaccine (active ingredient: ufrenmeran)?
DAICHIRONA (MONOVALENT, ORIGINAL) INITIAL APPROVAL is a marketed brand name for coronavirus (sars-cov-2) rna vaccine (active ingredient: ufrenmeran). Check FDA Drugs@FDA for the current US label holder and prescribing information.